**Core tip:** We report a 36-year-old Chinese woman diagnosed with systemic lupus erythematosus who initially presented with macrophage activation syndrome (MAS) and manifested respiratory failure. The administration of corticosteroid and cyclosporine A improved her respiratory depression along with all other symptoms. The clinical characteristics of MAS show great heterogeneity, and sufficient knowledge of these syndromes and early diagnosis are essential to improve prognosis. Corticosteroids are the mainstay of initial treatment for MAS.

INTRODUCTION
============

Macrophage activation syndrome (MAS) is defined as a specific secondary hemophagocytic lymphohistiocytosis (HLH) that refers particularly to those triggered by autoimmune diseases, most commonly, systemic juvenile idiopathic arthritis (s-JIA)\[[@B1]\]. MAS has also been reported at the onset of adult-onset Still's disease, systemic lupus erythematosus (SLE), rheumatoid arthritis, systemic vasculitides, and Sjogren's syndrome\[[@B2]\]. The reported prevalence of MAS associated with SLE ranges from 0.9% to 4.6%\[[@B3]\], and the mortality rate of MAS complicating adult SLE has been reported to range from 4.5%-9.8%\[[@B2],[@B4],[@B5]\]. The typical signs and symptoms of patients with MAS are fever, lymphadenopathy, hepatosplenomegaly and hemorrhagic manifestations. Abnormal laboratory tests include cytopenia, coagulopathy, hypertriglyceridemia and hyperferritinemia\[[@B4]\]. The incidence of MAS in rheumatic disorders is approximately 4.2% and the mortality rate is 40%\[[@B6]\]. Here, we report a 36-year-old Chinese woman who was diagnosed with SLE and MAS concurrently with the main manifestation of respiratory failure. To our knowledge, such a scenario has never been reported in detail before.

CASE PRESENTATION
=================

Chief complaints
----------------

A 6-d history of jaundice and a high fever of 39.4°C lasting one day.

History of present illness
--------------------------

The patient observed mild jaundice in her eyes and skin 6 d before admission, and an emerging high fever of 39.4°C lasting 1 d brought her to our hospital.

History of past illness
-----------------------

No previous illnesses.

Personal and family history
---------------------------

Unremarkable.

Physical examination upon admission
-----------------------------------

Physical examination revealed moderate skin and sclera jaundice, as well as enlarged bilateral cervical lymph nodes, which were freely movable and non-tender. Splenomegaly exceeding 3.5 cm below the costal margin was noted.

Laboratory examinations
-----------------------

On admission, the patient showed marked liver damage with alanine transaminase 224 U/L (normal 9-50 U/L), **a**spartate aminotransferase 409 U/L (15-40 U/L), direct bilirubin 129.4 μmol/L (0-6.8 μmol/L), and total bilirubin 160.8 μmol/L (3.42-20.5 μmol/L).

Imaging examinations
--------------------

Abdominal magnetic resonance imaging (MRI) showed multiple enlarged lymph nodes in the hilar area.

Further diagnostic work-up
--------------------------

Obstructive jaundice was initially suspected. However, abdominal MRI disproved this possibility. Severe infection was then suspected due to decreased white blood cells of 3.15 × 10^9^/L (3.5-9.5 × 10^9^/L) and continuing high grade fever. However, erythrocyte sedimentation rate and C-reactive protein were within the normal range, but an elevated ferritin level of 10620 μg/L (20-110 μg/L) was observed. Laboratory tests for wide range infection screening did not identify any infections (Table [1](#T1){ref-type="table"}). Even after liver protection treatment and empiric superior antibiotic therapy (meropenem), the patient had continued high fever and exacerbated liver function damage, which were complicated by newly emerged pancytopenia (Table [1](#T1){ref-type="table"}) and middle level seroperitoneum, as well as type I respiratory failure supported by arterial blood gas analysis of PO~2~: 55 mmHg (80-100 mmHg), PCO~2~: 32 mmHg (35-45 mmHg). Computed tomography suggested bilateral pleural effusion (Figure [1](#F1){ref-type="fig"}); therefore, the patient was offered assisted breathing and closed chest drainage. Considering the elevated serum ferritin level and early hematological involvement, the possibility of MAS was suspected and more laboratory tests for MAS and autoimmune diseases were conducted (Table [2](#T2){ref-type="table"}).

###### 

Laboratory data and infection work-up

  **Items**                            **Result**     **Reference values**
  ------------------------------------ -------------- ----------------------
  Sedimentation (mm/h)                 12             0-34
  C-reactive protein (mg/L)            5.6            0-10
  WBC (× 10^9^/L)                      2.41           3.5-9.5
  Neutrophils                          1.82           1.8-6.3
  PLT (× 10^9^/L)                      9              125-350
  Hb (g/L)                             66             115-150
  Triglyceride (mmol/L)                4.29           \< 1.7
  Fibrinogen (mg/dL)                   61             200-400
  D-dimer (mg/L)                       2.43           \< 0.55
  Total bilirubin (μmol/L)             201.9          3.42-20.5
  Direct bilirubin (μmol/L)            155.2          0-6.8
  Hepatitis virus DNA                  Not detected   
  HIV, EB-virus and cytomegalovirus    Not detected   
  IgG and IgM of *M. pneumoniae*       Negative       Negative
  Blood cultures for pathogens         Negative       Negative
  T-SPOT and acid-resistant staining   Negative       Negative
  Full-set tumor markers               Negative       Negative

PLT: Platelet; Hb: Hemoglobin; HIV: Human immunodeficiency virus.

![Pulmonary computed tomography scan images of the lungs before and after treatment. A: Coronal computed tomography scan image of the lungs before treatment with methylprednisolone and cyclosporine showing obvious bilateral pleural effusion (arrow); B: Pleural effusion had disappeared at the time of discharge (arrow).](WJCC-7-3859-g001){#F1}

###### 

Autoimmune work-up and biopsy results

  **Items**                                 **Result**                                                                    **Reference values**
  ----------------------------------------- ----------------------------------------------------------------------------- ----------------------
  ANA antibody                              1:320(+)                                                                      Negative
  Anti-Ro-52                                ++                                                                            Negative
  Anti-SS-A                                 +++                                                                           Negative
  Anticardiolipin IgM                       \+                                                                            Negative
  Anti-dsDNA                                Negative                                                                      Negative
  Anti-SM                                   Negative                                                                      Negative
  Complement C3 (g/L)                       0.439                                                                         0.79-1.52
  Complement C4 (g/L)                       0.18                                                                          0.16-0.38
  ANCA                                      Negative                                                                      Negative
  MPO+PR3                                   Negative                                                                      Negative
  IgG4 (g/L)                                0.164                                                                         0.03-2.01
  Soluble CD25 (pg/mL)                      8516                                                                          \< 6400
  Crushed red blood cells and Coombs test   Negative                                                                      Negative
  Natural killer cell function              Not able to complete                                                          
  Lymph node biopsy                         Kikuchi lymphadenitis, CD68/CD163 positive by immunohistochemistry analysis   Negative

ANA: Antinuclear antibody; ANCA: Antinuclear cytoplasmic antibody; MPO: Myeloperoxidase; PR3: Protease 3.

FINAL DIAGNOSIS
===============

Respiratory failure and MAS as an onset of SLE.

TREATMENT
=========

Intravenous methylprednisolone therapy of 1.5 mg/kg/d was initiated on the 7^th^ d, and 150 mg/d of cyclosporine A was added on the 10^th^ d. On the 14^th^ d, methylprednisolone was reduced to 1.0 mg/kg/d and 80 g intravenous immunoglobulin was initiated on the 10^th^ d. To our delight, the patient had a prompt favorable reaction to this treatment. Her fever subsided on the 8^th^ d, all disease indicators improved, the SPO~2~ increased to 96% and plural effusion improved (Figure [1](#F1){ref-type="fig"}). Oral corticosteroid and cyclosporine A were maintained to achieve long-term remission.

OUTCOME AND FOLLOW-UP
=====================

Following hospital discharge, the patient was in clinical remission during the 1-year follow-up period.

DISCUSSION
==========

MAS is defined as a specific secondary HLH that refers particularly to those triggered by autoimmune diseases. A defect in perforin-mediated cytotoxicity is the underlying mechanism\[[@B7]\]. Perforin mediates not only the killing of target cells, but also apoptosis of autologous cells. The decreased killing efficiency of target cells due to the gene defect leads to reactive proliferation of natural killer (NK) cells and T cells, and stimulates the excess release of pro-inflammatory factors by macrophages\[[@B8]\]. In addition, the apoptotic pathway is blocked, resulting in further accumulation and uninterrupted hyper-stimulation of immune cells and then a waterfall release of inflammatory factors and eventually the so-called "inflammatory storms"\[[@B8]\].

Pulmonary involvement in MAS has been described previously\[[@B4],[@B7]\], and symptoms include cough, dyspnea and respiratory failure, especially in cases triggered by respiratory viruses\[[@B9]\]. However, clinical data are obscure and may make limited sense for clinical work. The specific pathological process of hydrothorax and respiratory failure in SLE-MAS has not yet been elucidated. A possible mechanism may be that inflammatory factors act on the lung capillaries, causing inflammatory exudation and deterioration of gas exchange in the lungs, leading to pleural effusion and respiratory failure. Pulmonary infection may be an additional etiology at the early stage of the episode or may even be the trigger, and it may also merge during the episode and jointly aggravate the pulmonary condition. It has been reported that *Mycoplasma pneumoniae* infection has been linked to several extra-respiratory systems\[[@B10],[@B11]\]; thus, it is important for clinicians to exclude the possibility of infection when MAS is suspected, especially in the presence of respiratory failure.

Our patient was diagnosed with MAS and underlying SLE concurrently. For early recognition of MAS, it should be emphasized that a high ferritin level and/or a rapid ferritin increase seem to indicate a diagnosis of MAS rather than active rheumatic disease alone\[[@B12],[@B13]\]. Studies have shown that hyperferritinemia has the best sensitivity and specificity for indicating MAS and the relative reduction in platelet count appears to be the best early marker for identifying underlying SLE activity and MAS onset, following exclusion of thrombocytopenia caused by SLE disease activity itself\[[@B14]\]. Our case showed no macrophage hemophagocytosis in two bone marrow biopsies. There is consensus that pathologic proof of hemophagocytosis is not vital for the diagnosis of MAS/HLH and the absence of hemophagocytosis should not delay treatment of MAS/HLH\[[@B1],[@B4],[@B15],[@B16]\]. The recovery of our patient supports this. Even histiocytic hemophagocytosis itself is not necessarily abnormal, as histiocytes or macrophages can phagocytose aged or dying hematopoietic cells to maintain tissue homeostasis. Thus, it is important to define distinctive histiocytes in bone marrow to diagnose MAS\[[@B2]\].

Our patient fulfilled all the diagnostic criteria for HLH-2004, with the exception of hemophagocytosis and NK cell function. Despite studies showing discrepancies with respect to MAS characteristics, laboratory tests and therapeutic response between children and adults\[[@B2]\], many clinical guidelines and treatment trials have focused on pediatric patients due to lower morbidity in adults. Even the HLH-2004 criteria were originally created for children\[[@B17]\], but are now widely used as diagnostic criteria for adults. New diagnostic guidelines such as the 2005 s-JIA-MAS guidelines by Ravelli et al\[[@B18]\], the 2009 childhood-onset-SLE-MAS criteria by Parodi et al\[[@B14]\], and the 2016 EULAR/ACR/PRINTO-MAS criteria for s-JIA-MAS\[[@B19]\], are all focused on pediatrics. A scoring system known as the HScore was designed to help clinicians diagnose hemophagocytic syndrome\[[@B20]\], yet its robustness and efficiency in adults remain to be tested. The absence of standardized diagnostic criteria for adults may result in frequent missed or incorrect diagnoses, and consequently poor prognosis\[[@B7]\]. Furthermore, the pathogenic and pathogenesis of each MAS episode may vary due to different triggers\[[@B2],[@B21]\], and some researchers have found it important to formulate a robust set of specific diagnostic criteria and therapeutic strategies aimed at different etiologies\[[@B14],[@B21]\]. Large samples and high-quality analysis are required for this purpose.

Some experts have proposed the following triple simultaneous approach for the treatment of HLH: Support measures; The elimination of triggers (mainly infection); Suppression of the inflammatory response and cell proliferation (neoplasia)\[[@B7]\]. With regard to the treatment of SLE-MAS, there are currently no unified guidelines. Corticosteroids are thought to be the mainstay of initial treatment irrespective of the etiology, and can be administered alone or in combination with adjuvant drugs including methotrexate, cyclophosphamide, cyclosporine, tacrolimus, intravenous immunoglobulin and etoposide\[[@B2],[@B4]\]. Drug combinations should be given according to the etiology and characteristics of the episode. Physicians may also administer biological treatments such as rituximab, infliximab, etanercept, anti-interleukin 1r (anakinra) and interleukin-6 (tocilizumab), when patients show no response to first-line treatments\[[@B1],[@B4],[@B21]\].

CONCLUSION
==========

MAS should be considered when continued high fever complicated by multi-system damage occurs. International and multidisciplinary efforts for a robust set of specific diagnostic criteria and therapeutic strategies for SLE-MAS in adults are urgently needed, as early diagnosis and treatment are extremely critical for optimal prognosis\[[@B5]\].
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